Guardant Health
About: Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Employees: 2,021
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
106% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 31
50% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 6 (+2) [Q4]
29% more capital invested
Capital invested by funds: $2.83B [Q3] → $3.65B (+$819M) [Q4]
10% more funds holding
Funds holding: 267 [Q3] → 295 (+28) [Q4]
7% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 88
5.85% less ownership
Funds ownership: 102.56% [Q3] → 96.71% (-5.85%) [Q4]
48% less call options, than puts
Call options by funds: $29.5M | Put options by funds: $56.8M
Research analyst outlook
14 Wall Street Analysts provided 1 year price targets over the past 3 months
14 analyst ratings
Piper Sandler David Westenberg 46% 1-year accuracy 21 / 46 met price target | 48%upside $60 | Overweight Maintained | 6 May 2025 |
Scotiabank Sung Ji Nam 13% 1-year accuracy 3 / 23 met price target | 40%upside $57 | Sector Outperform Maintained | 5 May 2025 |
Canaccord Genuity Kyle Mikson 39% 1-year accuracy 12 / 31 met price target | 60%upside $65 | Buy Maintained | 1 May 2025 |
Stifel Daniel Arias 13% 1-year accuracy 2 / 16 met price target | 48%upside $60 | Buy Maintained | 1 May 2025 |
Barclays Luke Sergott 29% 1-year accuracy 18 / 63 met price target | 48%upside $60 | Overweight Maintained | 1 May 2025 |
Financial journalist opinion
Based on 14 articles about GH published over the past 30 days









